Announced
Synopsis
Moderna, a commercial-stage biotech, agreed to acquire OriCiro Genomics, a developer of a cell-free genome technology, for $85m. "With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing. OriCiro's technology strategically complements our manufacturing expertise and further accelerates our research and development engine. We look forward to welcoming the OriCiro team to Moderna," Stéphane Bancel, Moderna CEO.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.